MiR-133a has emerged as a tumor suppressor in non-small cell lung cancer (NSCLC), esophageal cancer (EC), prostate cancer (PC) and breast cancer (BC), targeting genes such as SOX4, EGFR, FSCN1, and COL1A1 [5]. Here, SOX4 is linked to pachyonychia congenita.